Real-time enrollment status for this residual, progressive or recurrent grade ii or iii meningioma clinical trial
Current Status
Recruiting
Checked: October 15, 2026 at 12:02 PM UTC
| NCT Number | NCT05023018 |
| Recruiting Status | Recruiting |
| Condition | Residual, Progressive or Recurrent Grade II or III Meningioma |
| Phase | PHASE2 |
| Target Enrollment | 30 participants |
| Active Locations | 5 sites in the US |
| Sponsor | Neonc Technologies, Inc. |
| Last Updated on CT.gov | September 15, 2026 (Sep 15, 2026) |
As of October 15, 2026: Clinical trial NCT05023018 is currently recruiting participants. This phase2 study for residual, progressive or recurrent grade ii or iii meningioma is actively seeking new participants at 5 locations across the United States. The study is sponsored by Neonc Technologies, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05023018 is actively recruiting participants as of October 15, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 5 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05023018 was last updated Sep 15, 2026 (September 15, 2026). HelloStudys verifies this status automatically.